Almirall seeks partnership
This article was originally published in Scrip
The Spanish pharmaceutical company Almirall is aiming to strike a deal for the development and commercialisation of its long-acting beta agonist, LAS100977. The new, unnamed chemical entity could be a step forward in the treatment of asthma and chronic obstructive pulmonary disease, the company says.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.